 |
 |

Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer—Invited Critique
Harvey G. Moore, MD
Arch Surg. 2009;144(2):134-135.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Preoperative combined modality therapy (CMT) including radiation (50.40 Gy) and fluorouracil-based chemotherapy followed by radical resection is the preferred treatment paradigm for locally advanced (T3-T4 and/or N1-N2) rectal cancer in the United States.1 Castaldo et al report data from a large cohort of patients with rectal cancer from the SEER registry that corroborate the finding, previously noted in single- and multi-institution reports,2-3 that complete or near-complete pathologic responders to CMT have significantly improved OS and DSS compared with poor responders. Evidence suggests that decreased distant failure in complete responders may be largely responsible for this phenomenon.2-3 Taken together, these studies strongly suggest that primary tumor response to CMT may be a reliable surrogate for systemic control and long-term outcome. One must avoid the temptation, however, to interpret these data as license to be less aggressive in treating complete or near-complete responders. For instance, Castaldo and colleagues . . . [Full Text of this Article] AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Improvement of Survival With Response to Neoadjuvant Radiation Therapy for Rectal Cancer
Eric T. Castaldo, Alexander A. Parikh, C. Wright Pinson, Irene D. Feurer, and Nipun B. Merchant
Arch Surg. 2009;144(2):129-134.
ABSTRACT
| FULL TEXT
|